BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

Journal: Science Translational Medicine

Published: 2020-02-19

DOI: 10.1126/scitranslmed.aax2625

Affiliations: 17

Authors: 34

Go to article
Institutions Share
Curie Institute, France 0.60
University of Liège (ULg), Belgium 0.09
Cancer GenomiCs.nl (CGC.nl), Netherlands 0.06
Biopôle, ENVA, France 0.04
Signalisation, Neurobiologie et Cancer, France 0.03
Animal Physiopathology and Biotherapy of the Muscle and Nervous System (PANTHER), France 0.03
Bioinformatics and Computational Systems Biology of Cancer, France 0.03
Genetics and Biology of Cancers, France 0.03
Queen's University, Canada 0.03
NIH NCI Center for Cancer Research (CCR), United States of America (USA) 0.03
Physiologie Animale et Systèmes d'Elevage (PHASE), INRAE, France 0.01
Immunity and Cancer Unit, France 0.01

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER